

FOR IMMEDIATE RELEASE

CRITICAL OUTCOME TECHNOLOGIES INC. SELECTED FOR CONSULATE GENERAL OF CANADA LIFE SCIENCES PARTNERING MISSION

London, Ontario (September 6, 2011): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to participate in a life sciences partnering mission to Boston, MA. This initiative is being held in conjunction with the BioPharm America conference taking place September 6-9, 2011.

“We are delighted to participate in this life sciences partnering mission to Boston and to be given the opportunity to share with a targeted audience the continued progress of our lead candidate, COTI-2,” said Dr. Wayne Danter, Chief Executive Officer (CEO). “The most recent results confirmed that Akt/Akt2 are important cellular targets for COTI-2 and will stimulate further discussions as we continue to evaluate licensing deal opportunities for COTI-2.”

COTI is one of nine Canadian companies that will participate in this partnering mission and has arranged a number of one-on-one meetings with pharmaceutical and drug development organizations. COTI will be represented by Dr. Wayne Danter, CEO, and Mr. Michael Barr, Vice President of Business Development and Marketing. As part of the partnering mission they will attend an exclusive networking dinner along with executives from several pharmaceutical companies.

Notice to Readers

Information contained in this press release may contain certain statements which constitute “forward-looking statements” within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statement “continue to evaluate licensing deal opportunities for COTI-2” is a forward-looking statement. This statement conveys the Company’s efforts to secure a licensing deal, but COTI is not in a position at this time to determine when and if a deal will be finalized. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management’s current expectations, estimates, projections and assumptions. Risks that could impact on these forward-looking statements are outlined in the Company’s annual information form. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge company specializing in accelerating the discovery of small molecules to enable new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Michael Barr
Vice President of Business Development and Marketing
519-858-5157
mbarr@criticaloutcome.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.